Salvatore Giovine - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Financial Officer
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
21 Oct 2021
Net transactions value
$0
Form type
3
Filing time
21 Oct 2021, 20:44:55 UTC
Next filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 233,596 $6.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on March 29, 2021 for 223,596 shares. On March 20, 2022, 25% of the underlying shares shall vest and the remaining shares shall vest in equal monthly installments until March 20, 2025.

Remarks:

Exhibit Index: 24.1 Power of Attorney